Omission of dacarbazine or bleomycin, or both, from the ABVD regimen in treatment of early-stage favourable Hodgkin”s lymphoma (GHSG HD13): an open-label, randomised, non-inferiority trial.

Behringer, K, Goergen, H, Hitz, F, Zijlstra, JM, Greil, R, Markova, J, Sasse, S, Fuchs, M, Topp, MS, Soekler, M, Mathas, S, Meissner, J, Wilhelm, M, Koch, P, Lindemann, H, Schalk, E, Semrau, R, Kriz, J, Vieler, T, Bentz, M, Lange, E, Mahlberg, R, Hassler, A, Vogelhuber, M, Hahn, D, Mezger, J, Krause, SW, Skoetz, N, Böll, B, von Tresckow, B, Diehl, V, Hallek, M, Borchmann, P, Stein, H, Eich, H, Engert, A.

http://www.ncbi.nlm.nih.gov/pubmed/25539730